capping protein inhibiting regulator of actin dynamicsGenealiases: CRAD · KIAA1211
Q-omics provides the consensus-scored CRACD profile across patient tissues and cancer cell-line models. CRACD expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, CRACD is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, CRACD protein abundance shows 26,797 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KIRP, COAD, and PDAC as cancer lineages where CRACD shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CRACD — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CRACD survival associations across molecular data types. CRACD RNA expression shows survival associations in the most cancer types (20), followed by mutation status (8) and mass-spec protein abundance (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CRACD RNA expression–survival associations across cancer types. High CRACD expression shows unfavorable associations in KIRP, MESO and ACC, but favorable associations in UCS, SCLC and HNSC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for CRACD RNA expression.
This table summarizes CRACD tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 10. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CRACD. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CRACD shows lower tumor expression in COAD and KIRC and higher tumor expression in BRCA, LUAD, HNSC and STAD. The COAD box plot shows higher CRACD RNA expression in normal versus tumor tissue (log2 FC = −2.477, t-test p < 0.001).
This table shows molecular features associated with CRACD in patient tissues and cancer cell lines. In patient samples, CRACD shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, CRACD RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and LARGE_INTESTINE.
